Skip to content
Catalyst

Vaccinium macrocarponFinding

Vaccinium macrocarpon decreases HOMA-IR

lowersModerate evidenceFindingreplicated ×1

01 · The sentence it was drawn from

“In terms of glycemic indicators, HOMA-IR was investigated in five studies, and the pooled estimates suggested that cranberry significantly reduced HOMA-IR (MD = −0.59; 95% CI: −1.05, −0.14; peffect = 0.01; Figure 4D), whereas cranberry supplementation did not show significant alterations to FBG (MD = −0.09; 95% CI: −0.23, 0.04; peffect = 0.17), HbA1c (MD = −0.16; 95% CI: −0.38, 0.05; peffect = 0.13), and fasting insulin (MD = −1.31; 95% CI: −2.85, 0.22; peffect = 0.09).”
Quoted verbatim from The Effects of Cranberry Consumption on Glycemic and Lipid Profiles in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
This finding among the 63 findings on its endpoint

Vaccinium macrocarpon

HOMA-IR

lowers

Effect as reported

−0.59mean difference

CI −1.05 to −0.14

Who
Adults aged 18 to 80 in randomized placebo-controlled trials of cranberry supplementation (healthy people and patients with overweight or obesity, diabetes, cardiovascular disease, metabolic syndrome or non-alcoholic fatty liver); pooled estimate from five studies
Dose studied
Pooled doses: capsules or tablets 144 to 1500 mg/day, powder 9 g/day, juice 240 to 750 mL/day; intervention length 2 weeks to 6 months

Moderate evidencePMID 38542695 · 2024

02 · The study

Study
meta-analysis
Duration
not reported

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6Y1CHJXSGJC3J5RBYMPS8TH